Abstract: A vehicle control apparatus includes front-wheel and rear-wheel driving systems, and a control system. The front-wheel driving system includes a first travel motor mechanically coupled to a front wheel of a vehicle and a first accumulator electrically coupled to the first travel motor. The rear-wheel driving system includes a second travel motor mechanically coupled to a rear wheel of the vehicle and a second accumulator electrically coupled to the second travel motor. The control system includes one or more processors and one or more memories communicably coupled to the one or more processors, and controls the first and second travel motors. When a difference between an SOC of the first accumulator and an SOC of the second accumulator is greater than a threshold value, the one or more processors change a torque distribution ratio between the first and second travel motors from a reference distribution ratio.

Abstract: A combination including (1) a molecule including the nucleotide sequence of SEQ ID NO: 1 and (2) an anticancer agent; and a method for treating a cancer, including administering an effective amount of the combination to a subject in need thereof. The anticancer agent may be an inhibitor of a BcL2 family molecule. The inhibitor of a BcL2 family molecule may be an expression inhibitor of the BcL2 family molecule or a function inhibitor of the BcL2 family molecule.

Abstract: An RNAi molecule for cancer treatment, including the nucleotide sequence of SEQ ID NO: 1 in an antisense strand; and a method for treating a cancer, including administering an effective amount of the RNAi molecule to a subject in need thereof. The antisense strand includes the nucleotide sequence selected from SEQ ID NOs: 11-30.

Abstract: Provided is a metastasis suppressing agent containing a HSP47 inhibitor.

Abstract: Provided is a medicine containing a HSP47 inhibitor to increase sensitivity of a cancer patient to a chemotherapeutic agent.

Abstract: The present invention relates to a pharmaceutical composition and a method for regenerating normal tissue from fibrotic tissue, the pharmaceutical composition and the method employing a collagen-reducing substance. In accordance with the present invention, normal tissue can be therapeutically regenerated from fibrotic tissue.

Abstract: This invention provides methods for preventing, treating or ameliorating one or more symptoms of a malignant tumor in a mammal in need thereof, by administering to the mammal a therapeutically effective amount of a composition comprising RNAi molecules, where the RNAi molecules can be active in reducing expression of Hsp47.

Abstract: The purpose of the present invention is to provide a novel tissue regeneration promoter and method for promoting tissue regeneration. The present invention pertains to: a composition for promoting tissue regeneration and/or promoting cell growth, the composition containing an RGD peptide; a method for promoting tissue regeneration and/or promoting cell growth using RGD peptide; and the like.

Abstract: The present invention relates to a pharmaceutical composition and a method for regenerating normal tissue from fibrotic tissue, the pharmaceutical composition and the method employing a collagen-reducing substance. In accordance with the present invention, normal tissue can be therapeutically regenerated from fibrotic tissue.

Abstract: The present invention relates to a pharmaceutical composition and a method for regenerating normal tissue from fibrotic tissue, the pharmaceutical composition and the method employing a collagen-reducing substance. In accordance with the present invention, normal tissue can be therapeutically regenerated from fibrotic tissue.

Abstract: This invention provides compositions and methods for preventing or treating a malignant tumor in a mammal in need thereof, by administering to the mammal a therapeutically effective amount of a composition comprising RNAi molecules, which RNAi molecules can be active in reducing expression of Hsp47, or a combination of RNAi molecules active for Hsp47 and p21.

Abstract: The present invention relates to a pharmaceutical composition and a method for regenerating normal tissue from fibrotic tissue, the pharmaceutical composition and the method employing a collagen-reducing substance. In accordance with the present invention, normal tissue can be therapeutically regenerated from fibrotic tissue.

Abstract: The purpose of the present invention is to provide a novel tissue regeneration accelerator and tissue regeneration method. The present invention relates to: a composition for accelerating tissue regeneration, accelerating cell differentiation and/or accelerating cell multiplication comprising a component selected from the group consisting of activated stellate cells, the decomposition product of activated stellate cells, MMP14, collagen that has been treated with MMP14, and the secretion product of activated stellate cells; a composition for suppressing cell multiplication comprising MMP14 suppressing material; and a cell cultivation substrate comprising collagen that has been treated with MMP14.

Abstract: The present invention relates to a pharmaceutical composition and a method for regenerating normal tissue from fibrotic tissue, the pharmaceutical composition and the method employing a collagen-reducing substance. In accordance with the present invention, normal tissue can be therapeutically regenerated from fibrotic tissue.